Second-line treatment for esophageal cancer with two chemotherapy drugs
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two chemotherapy drugs (liposomal irinotecan and 5-FU) for people with advanced esophageal cancer that didn't improve after first-line treatment. The goal is to see if this new combination can help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with esophageal squamous cell carcinoma (a type of cancer in the esophagus) that cannot be removed with surgery.
- Your first treatment (first-line) either didn't work or caused too many side effects.
- You have at least one measurable tumor that can be seen on scans.
- You are generally in good health, able to care for yourself and do light activity (ECOG 0 or 1).
- Your blood counts, liver and kidney function are within acceptable limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two chemotherapy drugs (liposomal irinotecan and cisplatin) given together with radiation therapy for locally advanced esophageal cancer. It aims to see if this treatment is safe and effective, potentially offering a new option for patients who cannot have surgery.
This study tests a new combination of two drugs (SHR-1701 and irinotecan liposome) for people with esophageal squamous cell carcinoma whose cancer has returned or spread after prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a short course of radiation combined with two drugs (raltitrexed and tislelizumab) for people with esophageal cancer that has returned after standard treatment. The goal is to see if these combinations can shrink tumors and improve survival.
This study tests a new form of the chemotherapy drug irinotecan (liposomal irinotecan) for people with metastatic colorectal cancer whose first treatment with oxaliplatin-based therapy has stopped working. The goal is to see if this drug can help shrink or control the cancer.
This trial tests a combination of two drugs (liposomal irinotecan and sintilimab) for people with stomach or gastroesophageal junction cancer that has progressed after at least one round of standard chemotherapy. The goal is to see if this combo can help shrink tumors or slow the cancer's growth.
This trial tests a new combination treatment with irinotecan liposome for advanced stomach or gastroesophageal junction cancer that has stopped responding to first-line therapy. It aims to see if this treatment can help control the cancer and improve outcomes.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.